Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service dialysis access cases in Montana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (245 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 330 | 21% |
| 2020 | 7 | 330 | 22% |
| 2021 | 3 | 230 | 25% |
AV fistula and graft creation, access circuit angioplasty and stenting. Professional codes (what the surgeon bills): CPT 36821, 36830, 36902, 36903, 36905, 36906, 36818, 36819.
Since 2021 dialysis (ESRD) patients may join Medicare Advantage, and they have moved to it far faster than the county average, so fee-for-service decline here overstates the real one even after adjustment.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Montana; 1 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 204 | 20,282−7.2%/yr | −7.2%/yr | 6.3 | 68% | 20,800 in 2030+0.5%/yr |
| Arizona | 33 | 3,680 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Superficial venous ablation | 6 | 568−13%/yr | −13%/yr | 2.90.5× | 94% | 490 in 2030−2.4%/yr |
| Peripheral arterial intervention |
Dialysis access in every state, and its device makers · Every procedure market in Montana · Every state · Compare with California
| ≈ 250 |
| – |
| 2026 est. | ≈ 250 | – |
| 2022 | 3 | 266 | 27% |
| 2023 | 2 | 205 | 30% |
| 2024 | 1 | 182 | 32% |
| 2025 from claims | – | 248 200–291 | 32% |
| 2026 forecast | – | 253 198–318 | 32% |
| 2027 forecast | – | 256 190–338 | 32% |
| 2028 forecast | – | 259 183–357 | 33% |
| 2029 forecast | – | 261 178–375 | 33% |
| 2030 forecast | – | 264 173–392 | 34% |
In 2025, 100% hospital outpatient.
| −7.6%/yr |
| 5.2 |
| 88% |
| 4,140 in 2030+2%/yr |
| Nevada | 20 | 2,124−8.8%/yr | −8.8%/yr | 7.7 | 96% | 2,190 in 2030+0.5%/yr |
| Washington | 30 | 2,051−12%/yr | −12%/yr | 2.8 | 19% | 1,780 in 2030−2.4%/yr |
| Colorado | 23 | 1,386−15%/yr | −15%/yr | 3.0 | 39% | 1,300 in 2030−1.1%/yr |
| Oregon | 16 | 1,041−9.9%/yr | −9.9%/yr | 2.6 | 56% | 1,090 in 2030+0.7%/yr |
| New Mexico | 7 | 658−16%/yr | −16%/yr | 3.0 | 83% | 1,090 in 2030+8.7%/yr |
| Utah | 9 | 647−6.1%/yr | −6.1%/yr | 3.1 | 40% | 580 in 2030−1.7%/yr |
| Hawaii | 8 | 567−14%/yr | −14%/yr | 4.6 | 62% | 560 in 2030−0.1%/yr |
| Idaho | 7 | 518−3.1%/yr | −3.1%/yr | 2.6 | 0% | 510 in 2030−0.2%/yr |
| Alaska | 8 | 491+1.8%/yr | +1.8%/yr | 4.1 | 49% | 400 in 2030−3.2%/yr |
| Wyoming | 1 | 101−4.5%/yr | −4.5%/yr | 0.9 | 0% | 100 in 2030+0.4%/yr |
| 5 |
| 334−8.2%/yr |
| −8.2%/yr |
| 1.70.3× |
| 0% |
| 370 in 2030+1.5%/yr |
| Carotid revascularization | 4 | 162−1.2%/yr | −1.2%/yr | 0.81.0× | 0% | 170 in 2030+1.3%/yr |
| Thrombectomy, IVC filters & venous stents | 2 | 147+16%/yr | +16%/yr | 0.80.6× | 0% | 150 in 2030+0.1%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
W L Gore & Associates leads with 100% of company spending on these surgeons in 2025.
In 2025, 1 company reported engagement with Montana’s surgeons worth $102 in consulting, speaking, meals and travel tied to these products, about $102 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 1 clearance or approval in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.